170729-73-4

Upstream product

• 159706-35-1 (S)-4-benzyl-3-phenylmorpholin-2-one 
• 785-56-8 3,5-bis(trifluoromethyl)phenyl carboxylic acid chloride 
• 170729-72-3 2-(R)-(3,5-bis(tri-fluoro-methyl)benzoyloxy)-3-(S)-phenyl-4-benzyl morpholine 

Downstream Products

• 170729-74-5 2-(R)-(1-(S)-(3,5-bis(tri-fluoromethyl)phenyl)ethoxy)-3-(S)-phenyl morpholine 
• 171338-33-3 [2R-[2α(R*),3α]]-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenylmorpholine 
• 170729-76-7 aprepitant 
• 170729-76-7 5-{(2R,3S)-2-[(S)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-3-phenyl-morpholin-4-ylmethyl}-2,4-dihydro-[1,2,4]triazol-3-one 

Relevant academic research and scientific papers

Structural optimization affording 2-(R)-(1-(R)-3,5- bis(trifluoromethyl)phenylethoxy)-3'-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4- triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist

Structural modifications requiring novel synthetic chemistry were made to the morpholine acetal human neurokinin-1 (hNK-1) receptor antagonist 4, and this resulted in the discovery of 2-(R)-(1-(R)-3,5- bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phe